Background:  INCA1 (inhibitor of CDK, cyclin A1 interacting protein 1), also known as HSD45, is a 236 amino acid nuclear protein that is highly expressed in testis and found at lower levels in ovary. Belonging to the INCA family, INCA1 interacts with cyclin A1, and along with other interacting, partners acts as substrate for the cyclin A1-CDK2 kinase complex. INCA1 exists as two alternatively spliced isoforms and is encoded by a gene located on human chromosome 17, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes.

Description: Rabbit polyclonal to INCA1

Immunogen: KLH conjugated synthetic peptide derived INCA1

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 27 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.